Table 1 Rates of complete cytogenetic response (CCyR) and major molecular response (MMR) to imatinib and dasatinib in the DASISION trial.
From: First-line treatment for chronic myeloid leukemia: dasatinib, nilotinib, or imatinib
| Â | % of patients | |
|---|---|---|
| Â | Imatinib 400 mg QD | Dasatinib 100 mg QD |
CCyR | Â | Â |
   3 months | 31 | 54 |
   6 months | 59 | 73 |
   9 months | 67 | 78 |
   12 months | 72 | 83 |
MMR | Â | Â |
   3 months | 0.4 | 8 |
   6 months | 8 | 27 |
   9 months | 18 | 39 |
   12 months | 28 | 46 |
Progression to AP/BP | 3.5 | 1.9 |